Stevanato Group Announces Voting Results from its Annual General Meeting
June 02 2022 - 4:05PM
Business Wire
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider
of drug containment, drug delivery and diagnostic solutions to the
pharmaceutical, biotechnology and life sciences industries
announced today that all resolutions proposed to Shareholders at
the Annual General Meeting of Shareholders (“AGM”) held virtually
on June 1, 2022 were passed.
Details of the resolutions submitted to, and approved by, the
AGM are included in the explanatory report prepared by the board of
directors of the Company, which is available on the Company’s
corporate website at https://ir.stevanatogroup.com/.
In the ordinary part of the AGM the Shareholders approved, among
other things, the annual financial statements for the financial
year ended on December 31, 2021 and the allocation of annual net
profits for the year, including a distribution of dividends in the
amount of EUR 0.051 for each ordinary share and class A share (net
of treasury shares). The dividend has a record date of June 14,
2022 and a dividend payment date of July 13, 2022. The Shareholders
also approved the compensation payable to the Company’s directors
for their service as members of the board and the additional
remuneration for the Company’s auditors, EY S.p.A. for the auditing
of the consolidated financial statements for the financial years
ending on December 31, 2021 and December 31, 2022, in accordance
with the Public Company Accounting Oversight Board (PCAOB)
standards. In addition, the Shareholders granted to the board of
directors – after revoking the existing authorizations – a new
authorization for the purchase and the disposal of ordinary and
class A treasury shares for the period and purposes indicated in
the explanatory report.
In the extraordinary part of the AGM, the Shareholders approved
all proposed amendments to the Company’s articles of association as
described in the explanatory report.
Further information regarding the AGM is available on the
investors’ section of Stevanato Group’s corporate website at
https://ir.stevanatogroup.com/, including the full text of the AGM
notice, explanatory report and other AGM materials. Shareholders
may request a hard copy of AGM materials, free of charge, by
emailing legal@stevanatogroup.com.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of
drug containment, drug delivery and diagnostic solutions to the
pharmaceutical, biotechnology and life sciences industries. The
Group delivers an integrated, end-to-end portfolio of products,
processes and services that address customer needs across the
entire drug life cycle at each of the development, clinical and
commercial stages. Stevanato Group’s core capabilities in
scientific research and development, its commitment to technical
innovation and its engineering excellence are central to its
ability to offer value added solutions to clients. To learn more,
visit www.stevanatogroup.com.
Forward-Looking Statements
This press release may include forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that reflect the current views of Stevanato Group S.p.A. (“we”,
“our”, “us”, “Stevanato Group” or the “Company”). The words “will”,
"can" and similar expressions (or their negative) identify certain
of these forward-looking statements. Forward-looking statements
contained in this press release may include, but are not limited
to, statements about Stevanato Group's AGM and our future financial
performance. These statements are neither promise nor guarantee but
involve known and unknown risks, uncertainties and other important
factors and circumstances that may cause Stevanato Group’s actual
results, performance or achievements to be materially different
from its expectations expressed or implied by the forward-looking
statements, including conditions in the U.S. capital markets,
negative global economic conditions, inflation, potential negative
developments in the COVID-19 pandemic, the impact of the conflict
between Russia and Ukraine, supply chain challenges and other
negative developments in Stevanato Group’s business or unfavorable
legislative or regulatory developments. The forward-looking
statements speak only as at their dates. The Company undertakes no
obligation to update any forward-looking statement or statements to
reflect events or circumstances after the date on which such
statement is made or to reflect the occurrence of unanticipated
events. New factors emerge from time to time, and it is not
possible to predict all of these factors. Further, the Company
cannot assess the impact of each such factor on our business or the
extent to which any factor, or combination of factors, may cause
actual results to be materially different from those contained in
any forward-looking statements. We caution you therefore against
relying on these forward-looking statements, and we qualify all of
our forward-looking statements by these cautionary statements.
Important factors that could cause actual results to differ
materially from those discussed in the forward‐looking statements
can be found under the heading "Risk Factors" in our most recent
reports on Form 20-F and other documents of Stevanato Group on file
with the U.S. Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220602005695/en/
Media Contact Stevanato Group -
media@stevanatogroup.com
Investor Relations Stevanato Group Lisa Miles, SVP
Investor Relations - lisa.miles@stevanatogroup.com
Stevanato (NYSE:STVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stevanato (NYSE:STVN)
Historical Stock Chart
From Apr 2023 to Apr 2024